Drugs /

poziotinib

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
poziotinib
NCI Definition [1]:
An orally bioavailable, quinazoline-based, mall-molecular and irreversible pan-epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity. Poziotinib inhibits EGFR (HER1 or ErbB1), HER2, HER4 and EGFR mutants, thereby inhibiting the proliferation of tumor cells that overexpress these receptors. EGFRs, cell surface receptor tyrosine kinases, are often upregulated in a variety of cancer cell types and play key roles in cellular proliferation and survival.

Clinical Trials

View Clinical Trials for poziotinib

Poziotinib has been investigated in 10 clinical trials, of which 6 are open and 4 are closed. Of the trials investigating poziotinib, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 8 are phase 2 (5 open).

EGFR Exon 20 Insertion, EGFR L858R, and EGFR L861Q are the most frequent biomarker inclusion criteria for poziotinib clinical trials.

Breast carcinoma, non-small cell lung carcinoma, and head and neck squamous cell carcinoma are the most common diseases being investigated in poziotinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Poziotinib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Poziotinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating poziotinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
hm781-36b, pan-her kinase inhibitor hm781-36b, hm781-36, nov120101
Drug Categories [2]:
Tyrosine kinase inhibitors
Drug Target(s) [2]:
EGFR, ERBB2, ERBB4
NCIT ID [1]:
C98838

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.